Talphera Achieves Milestone in NEPHRO CRRT Clinical Trial Progress
The pivotal NEPHRO CRRT trial has successfully reached a significant milestone, with enrollment surpassing 25%. This achievement is largely due to an increased recruitment rate facilitated by new clinical sites that have joined the study.
Enrollment Progress and Study Expectations
Talphera, Inc. (NASDAQ: TLPH) has proudly announced the enrollment of 17 patients in its critical NEPHRO CRRT clinical trial. This trial, targeting 70 patients, marks a key milestone necessary for advancing to the second tranche of financing that was previously disclosed. Reaching the 17-patient mark is a testament to the resilience and determination of the Talphera team and the momentum generated by the opening of new clinical sites.
"We're thrilled to announce that in just a week after reaching 15 patients, we’ve enrolled 17," stated Vince Angotti, CEO of Talphera. The influx of patients has resulted from strategic site selection aimed at enhancing recruitment outcomes. The company anticipates this positive trend will contribute to the timely completion of the trial by the end of the year.
About the NEPHRO CRRT Study
The NEPHRO CRRT study is designed to provide critical data on renal replacement therapy treatment options for adult patients. With oversight from a central IRB, the study involves a prospective, double-blinded approach across multiple U.S. hospitals' intensive care units. It will assess a total of 70 patients who cannot tolerate traditional anticoagulants such as heparin.
The primary aim of the study is to measure the mean post-filter activated clotting time when using Niyad compared to a placebo over the initial 24 hours. Additional critical evaluations will include tracking the filter lifespan, activated clotting time up to 72 hours, and number of necessary blood transfusions, among other key metrics.
Niyad and Nafamostat Overview
Nafamostat is recognized for its broad spectrum efficacy as a synthetic serine protease inhibitor that displays anticoagulant and anti-inflammatory properties. Niyad™, a formulation of nafamostat developed by Talphera, is currently under investigation as an anticoagulant for extracorporeal circuits. Having earned Breakthrough Device Designation from the FDA, Niyad is a vital component in Talphera’s research endeavors. The ongoing NEPHRO CRRT study aims to validate Niyad's safety and effectiveness in a clinical setting.
Additionally, Talphera is exploring LTX-608, an innovative formulation of nafamostat intended for direct IV infusion, which may provide therapeutic options for critical conditions such as acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).
About Talphera, Inc.
Talphera, Inc. is committed to the development of cutting-edge therapies designed for medically supervised environments. As a pioneering specialty pharmaceutical company, Talphera focuses on advancing Niyad™, its flagship product, which has the potential to significantly enhance patient care in intensive settings. The firm’s strategic initiatives reflect its dedication to improving health outcomes through innovative drug development.
Frequently Asked Questions
What is the NEPHRO CRRT trial?
The NEPHRO CRRT trial seeks to evaluate Niyad for patients requiring renal replacement therapy who cannot use heparin.
How many patients are expected to be enrolled in the trial?
The trial plans to enroll a total of 70 patients as part of its protocol.
What role does Niyad play in the study?
Niyad is being tested as an anticoagulant in patients undergoing extracorporeal circulation for renal replacement therapy.
When do the researchers expect to complete the study?
The study is anticipated to complete by the end of the year based on current enrollment projections.
Who is the CEO of Talphera?
Vince Angotti serves as the CEO of Talphera and has expressed optimism regarding the trial’s progress.
